🍷 AUD care is transplant care!
In this editorial, Klepper & Sherman highlight lessons from the LIFT Clinic, integrating prevention, treatment & routine PEth monitoring after liver transplantation.
Patient navigation reduced no-show rates to 9–15%.
🔗 https://t.co/ikXjqUiVzY
💊Are we over-immunosuppressing in LTx?
Mulder & den Hoed highlight evidence that tacrolimus-sparing strategies improve renal outcomes without increasing rejection.
Individualized immunosuppression balancing efficacy and toxicity. Future or present?
🔗 https://t.co/xMbS4aGqCQ
🧪 Can routine blood tests improve risk stratification before liver transplantation?
A retrospective study found that the pretransplant cystatin C/creatinine ratio was associated with post-LT outcomes.
🔗 https://t.co/pcEajXaP0n
⚖️ Hernia incarceration after TIPS: Complication or opportunity?
Incarceration risk rises after TIPS (20.9% vs 4.2%), but portal decompression may enable safer elective hernia repair and avoid emergency surgery.
The key: patient selection and timing
🔗 https://t.co/wq2F3sgoMq
⚖️ Is MELD truly etiology-neutral?
In an Indian cohort, ALD accounted for 75% (15/20) of deceased-donor LTs, while waitlisted patients who died had higher MELD than those transplanted (27 vs 22).
Does MELD reflect equal urgency across etiologies?
🔗 https://t.co/kdOAfd5DX2
♻️ One living donation, two liver transplants!
In 32 LDLTs for maple syrup urine disease, 27 explanted livers (84%) were reused as domino grafts.
1-year patient survival was 93.8% (MSUD) and 96.3% (domino recipients), supporting donor pool expansion.
🔗 https://t.co/EtsjK1B67H
📩 Day-7 mEAD in LDLT: Small-for-size physiology or graft failure?
Kalal et al. question lab-only criteria. In their reply, Stacey et al. clarify that lobe-specific scores are surrogate endpoints, not diagnostic tools.
📄 https://t.co/TYkWNezEKr
↩️ https://t.co/MNslXaZ3Yz
🏠 Hospital at Home for liver disease?
Early studies suggest this model may be safe and feasible for selected patients with cirrhosis. This review covers the evidence, care delivery, and challenges to broader implementation.
https://t.co/4rw9VDuQ2A
📖 Editorial | A tale of two cholangiopathies
LT for PBC declined from 6.2% to 2.9%, while PSC remained stable. Yet post-LT survival is nearly identical. Villamil highlights divergent therapeutic progress and the unmet need in PSC.
https://t.co/bJmfbGX7QL
💬 Who should receive a liver graft for unresectable colorectal liver metastases?
In this letter and reply, Acar and Cillo et al discuss prognostic factors, survival benefit, donor safety, and access to transplantation.
✉️ https://t.co/fH6fOJHEA2
↪️ https://t.co/vfLRw7vNKO
📚 MOC Opportunity – CME in #LiverTransplantation
This review covers best practices for first-line treatment of biliary strictures in PSC, emerging diagnostic approaches for cholangiocarcinoma, and strategies to minimize ERCP-related complications.
https://t.co/xUdHcWP0ux
🤖 Can robotic living donor hepatectomy become routine?
Evidence suggests lower donor morbidity, but remains largely non-randomized. This review presents a pragmatic 4P framework - People, Process, Platform & Proof - to guide safe, phased adoption.
🔗 https://t.co/nmPznvucJr
🦴Osteonecrosis after LT: Among 1,836 recipients, 3.5% developed ONFH, with 72% requiring surgery.
Corticosteroid exposure was not independently associated with ONFH, while pre-TX vulnerability and nutritional frailty emerged as relevant risk factors.
🔗 https://t.co/lpXD2SBKRr
💊 Which induction strategy is best for pediatric LT in autoimmune liver disease?
In 445 SPLIT recipients, IL2RA showed less early rejection (11% vs 21–28%), while ATG increased infection risk. Long-term outcomes were similar.
🔗 https://t.co/sXcXwzzuqM
🩸 Can frailty in cirrhosis be assessed without an in-person visit?
In 527 patients, the 7-biomarker Lab-LFI showed good discrimination for frailty (c-statistic 0.80). High scores were independently linked to pre-LT mortality/waitlist dropout (HR 1.77).
https://t.co/mU3C2ncpND
🧠 Physicians are expected to “do well” and “be well.”
Paul & Hutchison reflect on grief and burnout in transplant medicine, emphasizing confidential support, coaching and structured return-to-work pathways.
🔗 https://t.co/Ksf1DhIlT2
#LiverTransplantation
Low waitlist mortality may conceal unmet transplant need.
In this letter, Jacques et al. call for parallel living and deceased donor transplant pathways, emphasizing recipient autonomy, donor safety, and international mentorship.
https://t.co/Wg42jMCZNu
Which perfusion strategy is preferable after NRP in DCD LT?
In this randomized trial (n=50), D-HOPE & NMP showed comparable 1-year SAE rates, with graft survival of 88% vs 100% (p=0.07).
Findings support both, while highlighting need for larger trials.
https://t.co/AzeMqFFb4F
⏱️ Are DCD liver donors assessed using the same clock?
🌍 153 centers/17 countries: 76% of US vs 47% of non-US centers start acceptance waiting time at hemodynamic instability—not withdrawal of support.
A case for standardized assessment and reporting?
https://t.co/IOBhRF9k8d